HOME >> BIOLOGY >> NEWS
Fortress America?

rlying strategy seems sensible. Normally companies don't make remedies for the rare diseases thought most likely to be used as weapons, as there is no profit in it. So BioShield promises companies that it will buy particular drugs and vaccines for the threats it fears most, in theory giving the companies an incentive to do the rest. Why, then, has the response so far has been so unimpressive? Project BioShield has awarded contracts for seven products, worth $2 billion. Two are for antibody-based therapies for botulism and anthrax. One is for 10 million doses of the military's existing anthrax vaccine a concoction of bacterial debris whose alleged side effects have led some soldiers to prefer court-martial to vaccination. The single biggest slice of funding, $878 million, has been pledged to VaxGen of Brisbane, California, for 75 million doses of a purer, new-generation anthrax vaccine. An order is also expected for 20 million doses of an improved smallpox vaccine from the Danish firm Bavarian Nordic, while Project BioShield has provided $4 million to universities to fund basic pathogen research.

This is new territory for a government agency, which may explain the slow start. "the government has never done anything like this before," says Brad smith of the Center for Biosecurity. The Department of Homeland security must first decide what "designated threats" to target and then the Department of Health commissions drugs or vaccines designed to protect against them. So far the diseases it has picked extend to anthrax, botulism and smallpox.

This targeted "one bug, one drug" approach is, however, seen by some biodefence specialists as fundamentally misguided. Ken alibek, head of the soviet and then Russian bacterial weapons programme until 1992, says it allows attackers to create pathogens that evade or resist each remedy as fast as it is developed. "Based on the former soviet model, it takes three to four years to engineer a drug-resistant o
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-611-1210
New Scientist
5-Oct-2006


Page: 1 2 3

Related biology news :

1. Global community listens to TAU genetic researcher at EU Conference on Hearing Loss
2. Global warming is evaporating Arctic ponds, new study shows
3. Global heartbeat control suggests therapy for beating heart failure
4. Global survey of lizards reveals greater abundance of animals on islands than on mainland ecosystems
5. Global ocean sampling expedition
6. Global Nephrology gathers in Rio
7. Global study concludes attack rate of flu in kids is 55 percent lower with nasal spray vaccine
8. Global warming of the future is projected by ancient carbon emissions
9. Global warming is reducing ocean life, increasing atmospheric carbon dioxide, say scientists
10. Global warming will reduce ocean productivity, marine life
11. Global malaria map key weapon in fight against malaria, scientists say

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Fortress America

(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: